Quick Answer
Immuneering Corp reported Cash and Equivalents of $128.65 million for fiscal year 2025.
Immuneering Corp Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $128.65M | +255.9% |
| 2024 | $36.14M | -39.2% |
| 2023 | $59.41M | -18.2% |
| 2022 | $72.64M | -3.0% |
| 2021 | $74.89M | +101.9% |
| 2020 | $37.09M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $227.56M | — | +763.4% |
| June 30, 2025 | $26.36M | -55.9% | -26.5% |
| March 31, 2025 | $35.87M | -45.9% | -0.8% |
| December 31, 2024 | $36.14M | -39.2% | -39.5% |
| June 30, 2024 | $59.73M | -42.6% | -9.9% |
| March 31, 2024 | $66.29M | -14.4% | +11.6% |
| December 31, 2023 | $59.41M | -18.2% | -12.7% |
| September 30, 2023 | $68.04M | -11.0% | -34.6% |
- Immuneering Corp showed an increase of +255.9% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2020–2025 period, Immuneering Corp’s cash and equivalents has grown by 246.8% (from $37.09 million to $128.65 million).
- The most recent figure is from Immuneering Corp’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 6, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: